Suppr超能文献

接受β受体阻滞剂或钙拮抗剂治疗的急性心肌梗死患者的临床结局。一项对7922例首次住院心肌梗死患者的研究。

Clinical outcome of acute myocardial infarction in patients on treatment with beta-blockers or calcium antagonists. A study of 7,922 hospitalized first myocardial infarctions.

作者信息

Hansen O, Johansson B W, Gullberg B

机构信息

Section of Cardiology, Malmö General Hospital, Sweden.

出版信息

Cardiology. 1992;80(5-6):382-91. doi: 10.1159/000175029.

Abstract

To assess the effects of current treatments with beta-blockers or calcium antagonists on the clinical outcome of acute myocardial infarction (MI), enzymatically estimated infarct sizes, circulatory arrests from ventricular tachyarrhythmias, ventricular tachycardia (VT)/ventricular fibrillation (VF), and in-hospital mortality were analyzed retrospectively from 7,922 citizens of Malmö, Sweden, hospitalized due to a first MI between 1973 and 1987. Of these patients, 296 were on treatment with calcium antagonists, 393 on treatment with a beta 1-selective beta-blocker, 482 with a nonselective beta-blocker, and 95 on combined treatment with beta-blockers and calcium antagonists at the time of admission to hospital. In a set of multivariate analyses including several clinical characteristics, patients on treatment with a nonselective beta-blocker had a significantly lower peak aspartate aminotransferase (ASAT; difference -0.70 mukat/l, 95% CL: -1.24 to -0.16), whereas no significant relations between peak ASAT and treatment with cardioselective beta-blockers or calcium antagonists were found. Treatment with cardioselective beta-blockers or calcium antagonists, in contrast to treatment with a nonselective beta-blocker, were significant predictors of the occurrence of circulatory arrests from VT/VF. The relative risk of VT/VF in patients on cardioselective beta-blockers was 1.51 (95% CI: 1.12-2.03), and in patients on calcium antagonists 1.44 (95% CI: 1.03-2.02). None of the treatments were significantly associated with in-hospital mortality. In patients on beta-blockers or calcium antagonists when suffering their first MI, nonselective beta-blockade may reduce infarct size. Treatment with beta-blockers or calcium antagonists identified patients with an increased risk of circulatory arrests from VT/VF, but neither of the treatments were significantly associated with in-hospital mortality. We suggest that only minor differences exist between the effects of chronic treatment with beta-blockers and calcium antagonists on the outcome of an acute MI.

摘要

为评估当前使用β受体阻滞剂或钙拮抗剂治疗对急性心肌梗死(MI)临床结局、酶学估算梗死面积、室性快速心律失常导致的循环骤停、室性心动过速(VT)/心室颤动(VF)及住院死亡率的影响,我们对1973年至1987年间因首次MI住院的7922名瑞典马尔默市民进行了回顾性分析。这些患者中,296例正在接受钙拮抗剂治疗,393例接受β1选择性β受体阻滞剂治疗,482例接受非选择性β受体阻滞剂治疗,95例在入院时接受β受体阻滞剂与钙拮抗剂联合治疗。在一组包含多个临床特征的多变量分析中,接受非选择性β受体阻滞剂治疗的患者天门冬氨酸氨基转移酶(ASAT)峰值显著更低(差异为-0.70μkat/L,95%可信区间:-1.24至-0.16),而未发现ASAT峰值与心脏选择性β受体阻滞剂或钙拮抗剂治疗之间存在显著关联。与非选择性β受体阻滞剂治疗相比,心脏选择性β受体阻滞剂或钙拮抗剂治疗是VT/VF导致循环骤停发生的显著预测因素。接受心脏选择性β受体阻滞剂治疗患者发生VT/VF的相对风险为1.51(95%可信区间:1.12 - 2.03),接受钙拮抗剂治疗患者的相对风险为1.44(95%可信区间:1.03 - 2.02)。这些治疗均与住院死亡率无显著关联。在首次发生MI时接受β受体阻滞剂或钙拮抗剂治疗的患者中,非选择性β受体阻滞可能减小梗死面积。β受体阻滞剂或钙拮抗剂治疗可识别出VT/VF导致循环骤停风险增加的患者,但这两种治疗均与住院死亡率无显著关联。我们认为,β受体阻滞剂和钙拮抗剂的长期治疗对急性MI结局的影响仅存在微小差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验